Baxter International Inc.  

(Public, NYSE:BAX)   Watch this stock  
Find more results for Sebastian Huma�
+0.53 (0.78%)
Mar 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 68.00 - 68.62
52 week 65.94 - 77.31
Open 68.38
Vol / Avg. 2.11M/3.87M
Mkt cap 37.26B
P/E 19.28
Div/yield 0.52/3.03
EPS 3.56
Shares 543.53M
Beta 0.71
Inst. own 82%
May 18, 2015
Baxter International Inc 2015 Investor Conference Add to calendar
May 5, 2015
Baxter International Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
Apr 15, 2015
Q1 2015 Baxter International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 25, 2015
Baxter International Inc at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 10, 2015
Baxter International Inc. at Barclay's Global Healthcare Conference - Breakout Session - Webcast
Mar 10, 2015
Baxter International Inc at Barclays Healthcare Conference - Webcast
Mar 2, 2015
Baxter International Inc at Cowen Health Care Conference - Breakout Session - Webcast
Mar 2, 2015
Baxter International Inc at Cowen Health Care Conference
Jan 29, 2015
Q4 2014 Baxter International Inc Earnings Release
Jan 29, 2015
Q4 2014 Baxter International Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 11.72% 11.67%
Operating margin 16.70% 15.82%
EBITD margin - 25.92%
Return on average assets 8.17% 7.61%
Return on average equity 25.44% 23.47%
Employees 66,000 -
CDP Score - 78 C


1 Baxter Pkwy
DEERFIELD, IL 60015-4625
United States - Map
+1-847-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Baxter International Inc. (Baxter) is a global, diversified healthcare company. The Company through its subsidiaries, develops, manufactures and markets products that sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company operates in two segments: BioScience and Medical Products. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes. The Company also offers early-stage pipeline of protein therapeutics for autoimmune and allergic diseases.

Officers and directors

Robert L. Parkinson Jr. Chairman of the Board, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Robert J. Hombach CPA Chief Financial Officer, Corporate Vice President
Age: 49
Bio & Compensation  - Reuters
David P. Scharf Corporate Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Sebastian J. Bufalino Corporate Vice President, Controller
Age: 53
Bio & Compensation  - Reuters
Todd S. Young Corporate Vice President, Treasurer
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 59
Bio & Compensation  - Reuters
Ludwig N. Hantson Ph.D. Corporate Vice President, President - BioScience
Age: 52
Bio & Compensation  - Reuters
John Orloff M.D. Vice President, Global Head of Research and Development for Baxter BioScience
Bio & Compensation  - Reuters
Peter S. Hellman Lead Independent Director
Age: 65
Bio & Compensation  - Reuters
Thomas F. Chen Independent Director
Age: 64
Bio & Compensation  - Reuters